Adherium Doubles US Patient Base, Launches New Smartinhaler, Plans Capital Raise

Strong US Patient Growth Signals Momentum

Adherium Limited (ASX:ADR), a leader in connected respiratory medical devices, has reported a remarkable increase in its US commercial patient base, more than doubling to approximately 1,200 during the quarter ended 31 March 2025. This growth reinforces the company's ambitious target of reaching 9,000 remote patient monitoring (RPM) patients by the end of 2025. The surge is attributed to enhanced onboarding processes, deeper engagement with strategic partners, and expanded capacity within physician practices.

Key partnerships with networks such as Allergy Partners and SENTA have been instrumental, with provider activations doubling and new contracts signed, including entry into pulmonary specialty groups focused on COPD management. Additionally, steady adoption in programs run by AMC Health, Tenovi, and Intermountain Health further supports the platform's growing footprint.

Strategic Team Expansion to Accelerate Commercialisation

To sustain and accelerate this growth trajectory, Adherium has bolstered its US commercial team by appointing Jason Hochman as Head of US Commercial and David Haddad as Head of Product. Hochman brings extensive experience scaling RPM programs, while Haddad’s background in digital health management solutions is expected to enhance patient retention and engagement on the Hailie platform.

This leadership expansion underscores Adherium’s commitment to refining onboarding systems and scaling operations efficiently. The company is also leveraging patient data to develop AI-driven algorithms aimed at optimising medication adherence and care management workflows, positioning itself for future monetisation opportunities.

Product Innovation Unlocks New Market Segments

Adherium launched a new iteration of its Hailie Smartinhaler compatible with AstraZeneca’s AIRSUPRA and Breztri Aerosphere inhalers. The compatibility with Breztri Aerosphere extends coverage to 100% of triple therapy inhalers (ICS/LABA/LAMA) in the US, a critical advancement for managing moderate to severe COPD and asthma patients prone to frequent exacerbations.

Meanwhile, AIRSUPRA compatibility places Adherium at the forefront of evolving asthma care by supporting the only FDA-approved as-needed SABA/ICS rescue therapy. This innovation enables providers to monitor usage patterns and inhalation technique closely, feeding data into predictive algorithms that could anticipate exacerbations before they occur, thereby enhancing patient outcomes and reducing healthcare costs.

Strategic Partnerships and Market Access

Adherium’s strategic partnership with the Consortium of Independent Immunology Clinics (CIIC), the largest Group Purchasing Organisation (GPO) focused on allergy and immunology, provides streamlined access to over 500 healthcare providers across 33 states. This agreement is expected to accelerate practice onboarding and shorten sales cycles, creating a scalable financial model that incentivizes adoption.

In Australia, the company is actively engaging with key opinion leaders and major hospitals in Victoria to generate real-world evidence and clinical advocacy, aiming to broaden adoption among asthma and COPD stakeholders, including payers and government health systems.

Financial Position and Outlook

Adherium ended the quarter with a cash balance of $684,000, up from $387,000 in the previous quarter, supported by receipts from customers totaling $771,000. The company has reduced some operating costs, including administration and corporate expenses, while maintaining investment in sales, marketing, and staff to support growth initiatives.

The Board is planning a capital raise to fund ongoing expansion and product development, expressing confidence in successfully securing additional capital. Looking ahead, Adherium aims to rapidly onboard patients and physician practices, deepen engagement, expand RPM programs, and leverage AI-driven tools to enhance predictive care and long-term commercialisation.

Additionally, the company announced the impending appointment of Keven Gessner, a seasoned pharmaceutical and digital health executive, to its Board, bringing valuable expertise to guide US market adoption strategies.